Principal Investigator
Jay Spiegel
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20240831
Clinical Trial Summary
A Phase 2, Open-Label, Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in Patients with Relapsed or Refractory Mantle Cell Lymphoma
Phase
Phase II
Funding Agency/Sponsor
Institutional
Disease
Lymphoma
Contact Information
Phone Number
305-243-2647